• DaVita Inc. has reported past second-quarter 2026 results showing revenue of US$3,554.08 million and net income of US$265.4 million, with both basic and diluted earnings per share from continuing operations increasing compared with the prior year period.
• Beyond the financials, DaVita highlighted its role in strengthening the kidney transplant ecosystem through paired kidney exchange programs and support for non-directed living donors, underscoring its broader involvement in patient care beyond dialysis.
• We’ll now assess how this stronger earnings performance shapes DaVita’s investment narrative, particularly in light of its margin-focused efficiency efforts.

The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

DaVita Investment Narrative Recap

To own DaVita, you need to believe its core dialysis business can convert steady demand into consistent earnings while managing reimbursement and cost pressures. The latest quarter’s higher revenue and earnings per share support the margin-focused story in the near term, but do not remove key risks such as structurally lower treatment volumes and pressure from government reimbursement rates.

The most relevant recent announcement here is the August 2026 earnings release itself, which showed second quarter revenue of US$3,554.08 million and net income of US$265.4 million. This confirms that DaVita’s efficiency and cost-control efforts are feeding through to earnings, an important near term catalyst if margins are to hold up against slower treatment growth and reimbursement headwinds.

Yet beneath the stronger earnings, investors should be aware of the ongoing risk that reimbursement updates may lag rising costs and...

DaVita's narrative projects $15.7 billion revenue and $1.1 billion earnings by 2029. This requires 4.2% yearly revenue growth and an earnings increase of about $343.6 million from $756.4 million today.

Uncover how DaVita's forecasts yield a $208.57 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming DaVita could lift revenue to about US$16.5 billion and earnings to around US$1.1 billion, but this quarter’s results and the still uncertain path for technology driven cost savings show how far views can differ, and why you should compare these upbeat expectations with more cautious scenarios before deciding what you believe.

Explore 3 other fair value estimates on DaVita - why the stock might be worth just $208.57!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.